NewEdge Advisors’s Nephros NEPH Stock Holding History

NewEdge Advisors’s Portfolio NEPH Stock Details NEPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-27	Closed	-$132	–	4305
2025 Q4	$132	Buy	+27	New	+$138	﹤0.01%	4151
2024 Q2	–	Sell	-36	Closed	-$78	–	3939
2024 Q1	$78	Buy	+36	New	+$114	﹤0.01%	3712

Other funds holding NEPH

Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Cornerstone Capital Palo Alto, California $1B AUM 21.47% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

NewEdge Advisors's NEPH Position: Q1 2026 in Review

NewEdge Advisors sold out of Nephros (NEPH) in Q1 2026, closing a stake of 27 shares — an estimated $132 sold.

NewEdge Advisors first reported a position in NEPH in Q1 2024 and held it in 2 quarters. The position peaked at $132 in Q4 2025. 27 funds tracked by Wall St. Rank hold NEPH as of Q1 2026.

NewEdge Advisors reported no remaining Nephros position as of Q1 2026 after selling out during the quarter.
NewEdge Advisors sold 27 Nephros shares in Q1 2026, an estimated $132.
NewEdge Advisors first reported a position in Nephros in Q1 2024 and held it in 2 quarters.
NewEdge Advisors's Nephros position peaked at $132 in Q4 2025.
27 funds tracked by Wall St. Rank held Nephros as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.